← All candidates
One insider buy in the last year — $5.5K in all.
28 filings on record.
GOVXGeoVax Labs, Inc.
NasdaqCM · Healthcare · $4.21M
$0.4630
-2.56% · Sep 15
One insider buy in the last year — $5.5K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy◆ 6 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 2×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what GOVX ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$4.21M
Float
6.8M
75% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Spencer John N Jr
Bought $5.5K on Oct 17 — 10,000 sh @ $0.5498, held direct, 47% of their stake.
0 of 1 position beat the S&P
Chief Medical Officer
McKee Kelly T. Jr.
Bought $741.69 on Aug 7 — 1,107 sh @ $0.6700, held direct, 32% of their stake.
0 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
4 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
Context
Wall St
$10.00 avg target
+2059.8% vs today · 2 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 3 quarters beat
Q2 '26−$0.97 act+$1.18
Q1 '26−$2.62 act−$1.78
Q3 '25−$7.75 act−$1.13
Coverage
GeoVax targets Q4 phase 3 trial for MVA mpox vaccine with EMA expedited pathwayProactive · 08-10GeoVax Labs (GOVX) Stock Fair Value Moves Lower After Pipeline ShiftSimply Wall St. · 06-27GeoVax Labs (GOVX) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks · 06-12Why Is GOVX Stock Falling Today?Stocktwits · 05-26
The file stays open
28 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice